Please visit answersincme.com/FBF860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Paolo Tarantino, MD, PhD and Christopher Vetter, MD, MSc, FACS. In this activity, experts in breast cancer discuss the role of neoadjuvant human epidermal growth factor receptor 2 (HER2)–directed antibody-drug conjugates in HER2+ early-stage breast cancer. Upon completion of this activity, participants should be better able to: Recognize the rationale for investigating the use of anti-HER2 ADCs for the neoadjuvant treatment of HER2-positive early-stage breast cancer; Review the clinical implications of the data for anti-HER2 ADCs in the neoadjuvant treatment of HER2-positive early-stage breast cancer; and Outline clinical, multidisciplinary considerations for the use of anti-HER2 ADCs in the neoadjuvant treatment of HER2-positive early-stage breast cancer.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related